Drugs / CAN016
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07664150 | Jun 2026 → Dec 2028 expected | — | Canwell Biotech Limited | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-23 | CanWell Pharma Inc. | Regulatory CanWell Pharma Announces FDA Clearance of the IND for CAN016, a Dual-Payload ADC Targeting HER2, for ADC Pre-Treated Solid Tumors canwellpharma.com ↗
CanWell Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAN016, a HER2-targeting dual-payload ADC. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-23 | CanWell Pharma Inc. | CanWell Pharma Announces FDA Clearance of the IND for CAN016, a Dual-Payload ADC Targeting HER2, for ADC Pre-Treated Solid Tumors canwellpharma.com ↗ |
| 2026-02-03 | CanWell Pharma Inc. | A novel Dual-payload HER2 Targeted ADC, CAN016 as a Clinical Candidate to Overcome Enhertu Resistance canwellpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAN016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07664150 ↗ |
| Route | Intravenous | “administered intravenously into each patient” NCT07664150 ↗ |